SD-RAVEN-INDUSTRIES
31.8.2021 15:17:08 CEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN), the leader in Driverless Ag Technology , announced today it will showcase and demonstrate the company’s OMNi suite of technology at Farm Progress Show , one of the largest public farm shows in the United States. At the show, Raven will feature its industry-leading technology in the event’s Autonomy Zone, where the company will debut OMNiDRIVE™ on Case IH Magnum™ and showcase OMNiPOWER™ performing autonomous missions. The public can experience OMNi August 31 through September 2, 2021, from 8:00 a.m. – 5:00 p.m. daily.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005184/en/
Raven’s go-to-market strategy for OMNiDRIVE and dealer commitments for the technology are exceeding expectations. OMNiDRIVE was launched by Raven on May 12, 2021, with a year one limited release of 75 aftermarket systems. Today, all systems have been committed to by founding dealers. Through the remainder of the summer, the company is holding OMNiDRIVE demonstration events, where participants get a first-hand view of OMNiDRIVE controlling a driverless tractor pulling a grain cart and commanding it to sync with a harvester. Those interested in experiencing OMNiDRIVE and learning how the technology can dramatically impact their farm operations can sign up on ravenprecision.com/events .
OMNiDRIVE demonstrations this summer are being hosted by the company’s Founders Club members across the United States. Raven created the Founders Club, an elite group of dealers, to enhance the customer experience for ag professionals researching new driverless ag technology through OMNi’s first season of operation. The Founders Club involves intensive dealer training and demonstration requirements that help ag professionals think through a successful Path to Autonomy© for their operation.
“We recognize the challenges our farmers face daily,” said Jim Lilleberg, Director of Precision Ag and Machine Control for Titan Machinery, Inc. “Labor shortages, the need for efficiency improvements and scalability are all problems that OMNiDRIVE, now available for Case IH Magnum tractors, helps solve. We pride ourselves on being at the forefront of cutting-edge technology and the trusted partner to help enable it for our farmers. We feel this is the next major revolution in agriculture, and we are excited to be part of it!”
OMNiDRIVE™ is Raven’s aftermarket technology solution that transforms existing tractors into driverless machines. The technology connects, manages, and safely operates autonomous agricultural machinery and is compatible with:
- Case IH Magnum CVT (2014-2020 models): M250 / 280 / 310 / 340 / 380 (available in October 2021)
- New Holland CVT (2014-2020 models): T8.320 / 350 / 380 / 410 / 435 (available in October 2021)
- John Deere 8Rs Powershift and IVT (2010-current models)
OMNiPOWER™ is a self-propelled power platform that easily interchanges with farm implements, allowing the ag professional to perform multiple farming operations. OMNiPOWER is Raven’s premier platform that visually demonstrates the future of agriculture, drives innovation in the industry, and will accelerate the adoption of advanced autonomous solutions.
To learn more about what to expect from Raven at Farm Progress Show, visit ravenprecision.com/events/farm-progress-show .
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) provides innovative, high-value products and systems that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and aerospace and defense solutions, and the company’s groundbreaking work in autonomous systems is unlocking new possibilities in areas like farming, national defense, and scientific research. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, and unmatched service. For more information, visit https://ravenind.com/
.
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005184/en/
Link:
Social Media:
https://www.facebook.com/ravenprecision/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
